Our team has extensive expertise in developing novel treatments using RNA modalities and we are building a robust pipeline filled with multiple first-in-class candidates focused on preventing drug resistance in various cancers.
Replicate Bioscience (Replicate) is targeting multiple mechanisms of action (MOA) as it seeks to identify improved regimens in oncology, including breast cancer, lung cancers, and prostate cancer.
Replicate aims to maximize the potential of its SynRGY platform technology through partnerships in infectious diseases, including for COVID-19. We work in partnership with leading commercial organizations and academic labs to help advance infectious disease candidates into the clinic.
Since our launch in 2020, we have entered into strategic collaborations with Immunomic Therapeutics and Duke University.